| Prev Close | 35.90 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 29.95 / 58.95 |
| Avg Volume | 698.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 40.34M |
| Market Cap | 1.44B |
| EPS | -1.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 637,865 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 5,288,719, an increase of 13.72% since 08/15/2017.
The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent
Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,627,603 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 4,650,854, an increase of 53.84% since 07/31/2017.
Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction   Â
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,240,223 share decrease in total short interest for Pacira Pharmaceuticals Inc. , to 5,113,726, a decrease of 19.52% since 02/28/2017.
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the November 17th expiration.
Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities
Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
